Welcome to our dedicated page for Mynd Life Scienc news (Ticker: MYNDF), a resource for investors and traders seeking the latest updates and insights on Mynd Life Scienc stock.
News and updates for MYND Life Sciences Inc. (MYNDF) reflect its activities as a clinical-stage life sciences and medical biotech drug research and development company. The company’s news releases describe a focus on neuro-pharmaceutical and novel drug development, diagnostics, and vaccines, with particular emphasis on depression and inflammation-related diseases.
Recent announcements highlight MYND’s efforts to develop and commercialize a proprietary biomarker test for depression, including Major Depressive Disorder (MDD) and treatment-resistant depression (TRD). The company has discussed the MYND Anti-Inflammatory Peptide (MAP) test, which it describes as a biomarker aimed at diagnosing and monitoring depression by tracking neuroinflammation. News items often emphasize the goal of bringing a depression-focused biomarker test to market and the potential for this proprietary biomarker to support personalized patient management strategies.
Company news also covers corporate and financial developments, such as proposed share issuances to remove or restructure debt, shares-for-debt agreements, and other balance sheet changes. These disclosures explain how MYND is addressing outstanding indebtedness and debentures through the issuance of common shares, including transactions involving related parties under Canadian securities rules.
Regulatory and governance updates form another important category of news. MYND has reported on a management cease trade order (MCTO) granted under National Policy 12-203 due to delays in filing annual financial statements linked to significant restructuring of its debt and equity. The company’s news releases describe the scope of the MCTO, its impact on insiders, and the requirement to issue periodic default status reports.
Visitors to this page can review MYND Life Sciences’ historical and ongoing disclosures about its depression biomarker work, neuro-pharmaceutical research, capital structure changes, and regulatory reporting status, as presented in its official news releases.
Summary not available.
Summary not available.
Summary not available.
MYND Diagnostics has announced its involvement in a $3 million clinical trial funded by the Government of Australia, aimed at evaluating psilocybin-assisted psychotherapy for treatment-resistant depression. The trial will employ MYND's proprietary biomarkers to monitor patient responses and progress. Conducted by Dr. Paul Fitzgerald at Monash University, this phase 2b trial could lead to a multi-site phase 3 trial within a year, paving the way for potential regulatory approval by the Therapeutic Goods Association. MYND also anticipates entering more clinical trials in 2022/2023 to advance its biomarker development.
MYND Life Sciences Inc. has entered a Collaborative Research Agreement with the University of British Columbia to explore novel therapies for neurological diseases. The focus is on developing precision medicines, particularly those involving Psilocybins, aimed at improving treatment outcomes for conditions like dementia.
MYND is advancing various clinical programs, including a pivotal trial for novel biomarkers for treatment-resistant depression, with plans for additional clinical trials in 2022/2023. The company also announced the departure of COO Jordan Cleland, with Dr. Chahaat Singh assuming operational responsibilities.
MYND Life Sciences has completed the acquisition of intellectual property rights to use psychedelics for treating dementia, including Alzheimer's disease, from Cava Healthcare. This acquisition is expected to enhance MYND's capabilities in psilocybin-assisted therapy, which is aimed at addressing a condition that affects 44 to 50 million people globally. MYND issued 450,000 shares at $0.85 each and made a cash payment of $120,000. An annual royalty of $240,000 or 4% of net sales will also be paid. The acquisition positions MYND as a leader in psychedelic therapeutics for dementia.
MYND Life Sciences Inc. (CSE: MYND, OTC: MYNDF) announced the completion of its National Phase filing for a Patent Cooperation Treaty (PCT) application related to a method of immune modulation targeting a specific gene. CEO Dr. Lyle Oberg stated that building a solid intellectual property portfolio is crucial for long-term shareholder value. The PCT enables simultaneous patent protection across multiple countries. MYND aims to advance its drug pipeline to file for Innovative New Drug (IND) application. The company has also engaged Hybrid Financial Ltd. for marketing services.
MYND Life Sciences has received a grant of $45,600 from the Government of Canada to support research on the effects of psilocybin in treating brain diseases. The funding will aid a project titled Phytochemical-analog(s) as a novel method for management of treatment-resistant depression, running from November 2021 to March 2022. The project aims to explore how psilocybin analogs can modulate brain function by targeting specific gene pathways. The company is committed to advancing neuro-pharmaceutical innovations.
MYND Diagnostics, a subsidiary of MYND Life Sciences, has launched a clinical validation study for its proprietary MAP biomarker test aimed at aiding the diagnosis and monitoring of Multiple Sclerosis (MS). The study, expected to start in Q1 2022, will quantify MAP levels in MS patients' blood samples compared to controls. Successful results could lead to an FDA approval submission in H2 2022, making the test available through healthcare providers. The global MS therapeutic market was valued at $22.99 billion in 2018 and is projected to reach $28 billion by 2026.
MYND Life Sciences has announced the initiation of a clinical validation study for its proprietary biomarker testing in Alzheimer's Disease (AD) diagnostics. The study, conducted by its subsidiary MYND Diagnostics, aims to utilize the MAP biomarker to enhance early diagnosis and monitoring of AD. The validation is set to commence in Q1 2022, with anticipated FDA submission for approval in H2 2022. Currently, around 44 million people are affected by AD worldwide, and the diagnostics market was valued at USD 6.6 billion in 2020, projected to reach USD 9 billion by 2026.